Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC raised its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 3.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,977,082 shares of the company's stock after acquiring an additional 66,459 shares during the quarter. Geode Capital Management LLC owned approximately 2.32% of Syndax Pharmaceuticals worth $38,066,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in SNDX. Barclays PLC increased its position in shares of Syndax Pharmaceuticals by 143.4% during the third quarter. Barclays PLC now owns 187,629 shares of the company's stock worth $3,612,000 after purchasing an additional 110,535 shares in the last quarter. Y Intercept Hong Kong Ltd grew its holdings in shares of Syndax Pharmaceuticals by 319.4% during the third quarter. Y Intercept Hong Kong Ltd now owns 81,302 shares of the company's stock worth $1,565,000 after buying an additional 61,916 shares in the last quarter. Two Sigma Advisers LP raised its position in shares of Syndax Pharmaceuticals by 7.7% in the third quarter. Two Sigma Advisers LP now owns 669,352 shares of the company's stock valued at $12,885,000 after buying an additional 48,100 shares during the last quarter. Sphera Funds Management LTD. raised its position in shares of Syndax Pharmaceuticals by 25.9% in the third quarter. Sphera Funds Management LTD. now owns 1,034,846 shares of the company's stock valued at $19,921,000 after buying an additional 212,799 shares during the last quarter. Finally, State Street Corp lifted its stake in shares of Syndax Pharmaceuticals by 4.1% in the third quarter. State Street Corp now owns 3,770,826 shares of the company's stock worth $72,588,000 after buying an additional 148,491 shares in the last quarter.

Syndax Pharmaceuticals Price Performance

Shares of NASDAQ:SNDX traded down $0.24 during midday trading on Wednesday, reaching $13.07. 2,733,642 shares of the company's stock were exchanged, compared to its average volume of 1,278,437. The stock has a market cap of $1.12 billion, a price-to-earnings ratio of -3.60 and a beta of 0.86. Syndax Pharmaceuticals, Inc. has a fifty-two week low of $12.75 and a fifty-two week high of $25.34. The firm's 50 day simple moving average is $17.03 and its two-hundred day simple moving average is $19.16.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last announced its earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share for the quarter, topping the consensus estimate of ($1.13) by $0.15. The company had revenue of $12.50 million for the quarter, compared to analysts' expectations of $9.16 million. During the same period last year, the business earned ($0.73) EPS. Equities research analysts predict that Syndax Pharmaceuticals, Inc. will post -2.39 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. StockNews.com cut shares of Syndax Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, November 23rd. JPMorgan Chase & Co. upped their price target on Syndax Pharmaceuticals from $33.00 to $38.00 and gave the company an "overweight" rating in a research report on Thursday, November 21st. Stifel Nicolaus increased their price target on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the company a "buy" rating in a report on Monday, October 14th. The Goldman Sachs Group boosted their price objective on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. Finally, UBS Group assumed coverage on Syndax Pharmaceuticals in a research note on Thursday, October 24th. They issued a "buy" rating and a $37.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $36.90.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).